Human monoclonal antibodies to CTLA-4

Details Human monoclonal antibodies to CTLA-4 Human monoclonal antibodies to CTLA-4

2007-10-31

2010-11-02

Ouspenski, Ilia (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

Reexamination Certificate

active

07824679

ABSTRACT:
In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4681581 (1987-07-01), Coates
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4735210 (1988-04-01), Goldenberg
patent: 4740461 (1988-04-01), Kaufman
patent: 4816397 (1989-03-01), Boss et al.
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5102990 (1992-04-01), Rhodes
patent: 5151510 (1992-09-01), Stec et al.
patent: 5194594 (1993-03-01), Khawli et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: RE35500 (1997-05-01), Rhodes
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5648471 (1997-07-01), Buttram et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693792 (1997-12-01), Torii et al.
patent: 5697902 (1997-12-01), Godenberg
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5750172 (1998-05-01), Meade et al.
patent: 5756687 (1998-05-01), Denman et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5777085 (1998-07-01), Co et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6207156 (2001-03-01), Kuchroo et al.
patent: 6255458 (2001-07-01), Lonberg et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 7109003 (2006-09-01), Hanson et al.
patent: 7132281 (2006-11-01), Hanson et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: 2003/0086930 (2003-05-01), Mueller et al.
patent: 2008/0233116 (2008-09-01), Hanson et al.
patent: 2205680 (1998-11-01), None
patent: 1021-2002 (2002-05-01), None
patent: 0 216 846 (1987-04-01), None
patent: 0 323 997 (1989-07-01), None
patent: 0 338 841 (1989-10-01), None
patent: 0 463 151 (1992-01-01), None
patent: 0 546 073 (1993-06-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 256 055 (1998-02-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/22645 (1992-12-01), None
patent: WO 92/22647 (1992-12-01), None
patent: WO 92/22670 (1992-12-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 94/00569 (1994-01-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 94/29444 (1994-12-01), None
patent: WO 95/01994 (1995-01-01), None
patent: WO 95/03408 (1995-02-01), None
patent: WO 95/24217 (1995-09-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 96/14436 (1996-05-01), None
patent: WO 96/22380 (1996-07-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/13852 (1997-04-01), None
patent: WO 97/20574 (1997-06-01), None
patent: WO 97/38137 (1997-10-01), None
patent: WO 98/04281 (1998-02-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/42752 (1998-10-01), None
patent: WO 98/46996 (1998-10-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 00/32231 (2000-06-01), None
patent: WO 01/14424 (2001-03-01), None
United States Patent and Trademark Office, “Notice of Allowance and Fee(s) Due,” U.S. Appl. No. 11/128,900, filed Mar. 25, 2008.
United States Patent and Trademark Office, “Notice of Allowability,” U.S. Appl. No. 11/128,900, filed Mar. 25, 2008.
U.S. Appl. No. 11/128,900, filed Dec. 29, 2005, Hanson et al.
U.S. Appl. No. 11/981,771, Not Yet Published, Hanson et al.
U.S. Appl. No. 11/981,824, Not Yet Published, Hanson et al.
Alegre et al., Regulation of surface and intracellular expression of CTLA4 on mouse T cells,:J. Immunol., 157:4762-4770 (1996).
Allison & Krummel, “The Yin and Yang of T cell costimulation, ”Science, 270:932-933 (1995).
Balzano et al., “CTLA-4 and CD28: Similar proteins, neighbouring genes,”Int. J. Cancer: Supplement, 7:28-32 (1992).
Barker and Dayhoff, “Detecting distant relationships: computer methods and results,”Atlas of Protein Sequence and Structure, pp. 101-110 (vol. 5, National Biomedical Research Foundation (1972).
Blair et al., “Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XLinduction,”J Immunol, 160:12-15 (1998).
Blake and Litzi-Davis, “Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies,”Bioconjugate Chem., 3:510-513 (1992).
Boussiotis et al., “Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation,”Proc Natl Acad Sci USA, 90:11059-11063 (1993).
Bowie et al., “A method to identify protein sequences that fold into a known three-dimensional structure,”Science, 253:164-170 (1991).
Bruggemann et al., “A repertoire of monoclonal antibodies with human heavy chains from transgenic mice,”PNAS USA, 86:6709-6713 (1989).
Bruggemann and Neuberger, “Generation of antibody repertoires in transgenic mice,”Methods: A companion to Methods in Enzymology, 2:159-165 (1991).
Bruggemann et al., “Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus,”Eur. J. Immunol., 21:1323-1326 (1991).
Bruggemann and Neuberger, “Strategies for expressing human antibody repertoires in transgenic mice,”Immunology Today, 17:391-397 (1996).
Brunet et al., “A new member of the immunoglobulin superfamily—CTLA-4,”Nature, 328:267-270 (1987).
Bumpers et al., “Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice,”J. Surgical Res., 61:282-288 (1996).
Castan et al., “Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues,”Immunology, 90:265-271 (1997).
Chen et al., “Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4,”Cell, 71:1093-1102 (1992).
Chen et al. “Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JHlocus,”International Immunology, 5:647-

Affiliated with

Also associated with

Rating

Human monoclonal antibodies to CTLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibodies to CTLA-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to CTLA-4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4239103